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Neisseria meningitidis serogroup A capsular polysaccharide (MenA CPS) consists of (1→ 6)-2-
acetamido-2-deoxy-α-D-mannopyranosyl phosphate repeating units, O-acetylated at position
C3 or C4. Glycomimetics appear attractive to overcome the CPS intrinsic lability in physio-
logical media, due to cleavage of the phosphodiester bridge, and to develop a stable vaccine
with longer shelf life in liquid formulation. Here, we generate a series of non-acetylated
carbaMenA oligomers which are proven more stable than the CPS. An octamer (DP8)
inhibits the binding of a MenA specific bactericidal mAb and polyclonal serum to the CPS,
and is selected for further in vivo testing. However, its CRM197 conjugate raises murine
antibodies towards the non-acetylated CPS backbone, but not the natural acetylated form.
Accordingly, random O-acetylation of the DP8 is performed, resulting in a structure (Ac-
carbaMenA) showing improved inhibition of anti-MenA CPS antibody binding and, after
conjugation to CRM197, eliciting anti-MenA protective murine antibodies, comparably to the
vaccine benchmark.
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Vaccination, one of the most important advancements ofmodern medicine, is considered the most cost-effectivestrategy to protect the population from infectious dis-
eases by the WHO1. Although well-established vaccines are
commonly and successfully employed against a large number of
diseases, the increased occurrence of antimicrobial resistance
has raised the need for new and more efficient vaccines to
prevent infections. In order to increase safety margins and
improve efficacy of traditional vaccines, based on live-
attenuated or whole-cell killed microorganisms, effort has
been directed to the development of subunit vaccines, in which
only a purified microbial component is administered. Amongst
the subunit vaccines, carbohydrate-based vaccines have been
applied to a variety of bacterial infections (Haemophilus influ-
enzae type b, Streptococcus pneumoniae, Neisseria meningitidis
and others)2. The vast majority of pathogens exposes a dense,
often highly conserved array of glycan structures on their
surface that exert a protective function against the host’s
immune defense and are essential for their pathogenicity.
Therefore, they represent attractive targets for vaccine design3.
Typical examples are capsular polysaccharides (CPS) of
encapsulated bacteria and lipopolysaccharides of Gram-
negative bacteria. A major drawback of polysaccharide-based
vaccines is their limited clinical efficacy. In fact, they are poorly
immunogenic in infants, young children and immunocom-
promised patients. They do not induce immunological memory
and their response is therefore not boosted by subsequent
immunizations4–6. This derives from the fact that carbohy-
drates raise a T cell-independent immune response, hallmarked
by the production of low affinity IgM antibodies and no con-
ventional B cell-mediated immunological memory. Conjugation
of CPS to a carrier protein, such as tetanus or diphtheria tox-
oids (TT, DT), or the nontoxic mutant of diphtheria toxin
(Cross-Reacting Material 197, CRM197), leads to glycoconju-
gates with T cell-dependent properties7. Glycan-protein anti-
gens enable memory B cell proliferation, ensuring long-lasting
protection of the host. These features combined with the
extensive clinical experience render glycoconjugates amongst
the safest and most efficacious vaccines developed so far, and
their generation has been one of the greatest success stories in
the biomedical sciences4,8,9.
The Gram-negative encapsulated bacterium N. meningitidis is a
major cause of bacterial meningitis occurring beyond the neo-
natal period. Six out of thirteen serotypes (A, C, B, W, Y, and X)
are responsible of more than 90% of the reported infections10.
Particularly, serogroup A (MenA) causes epidemic meningo-
coccal disease in developing countries, predominantly throughout
what is known as the African meningitis belt, with over 250
million of at-risk population11,12. The recent introduction of a
MenA capsular polysaccharide-conjugate vaccine has dramati-
cally decreased the disease incidence13,14, but the development
and manufacture of an efficient glycoconjugate vaccine in fully
liquid, shelf stable formulation, which would avoid the recon-
stitution of the lyophilized formulation before injection, remains
a great challenge. The MenA capsular polysaccharide (MenA
CPS) consists of (1→ 6)-linked 2-acetamido-2-deoxy-α-D-man-
nopyranosyl phosphate repeating units (Fig. 1)15,16. It has been
shown that isolated MenA polysaccharide carries acetyl esters
primarily at its C3-hydroxyl (80%) with limited acetylation of the
C4-hydroxyl (10%). Recent studies however on meningococcal
cells by high-resolution magic angle spinning NMR (HRMAS)
spectroscopy have revealed a substitution at the C3-OH of 50-
60% and at the C4-OH of 25–30%15,17. Like other phosphodiester
containing polysaccharides, MenA is known to be poorly
hydrolytically stable18. The intrinsic instability of MenA CPS is
enhanced by the axial orientation of the acetamido functionality
at C-2, which assists the facile cleavage of the anomeric phos-
phodiester linkage in aqueous environment19,20. The faster
kinetic of hydrolysis of MenA polysaccharide compared to other
antigens is well established19. A recent report suggests that a
MenA-TT glycoconjugate is more stable to pH and temperature
variation compared to the unconjugated polysaccharide, but this
work only evaluated the activity of the conjugate in terms of
antigenicity and not immunogenicity, and the effect of (partial)
degradation on human immunization is unpredictable21. Gen-
erally, stability issues can be controlled by storage at 2–8 °C or
overcome by freeze-drying. However, the availability of stable
antigens, independent from the efficiency of the cold chain used
for vaccine distribution, and with the potential of longer shelf life
in liquid formulation is extremely attractive22.
Much effort is currently devoted to the generation of syn-
thetic carbohydrate vaccines, in which chemically made oligo-
saccharides are used as antigens in conjugate vaccines23,24. The
use of synthetic material has many advantages, including well-
defined size, minimal (if any) batch-to-batch variation, and
controlled conjugation chemistry. Indeed, synthetic carbohy-
drate vaccines have reached the market. In all these efforts
fragments of the natural polysaccharides are copied through
organic synthesis. Strategies for the chemical or enzymatic
synthesis of natural MenA structures have been proposed25,26.
Differently from these approaches, we envisaged the use of
synthetic chemistry to generate stabilized MenA
glycomimetics27,28. Mimics, in which structural changes are
implemented to improve specific features of the natural poly-
saccharide have so far not been incorporated in conjugate
vaccines inducing protective immune responses29. Given the
exquisite recognition of antigens by antibodies it is a grand
challenge to develop mimetics that sufficiently mimic their
natural counterpart so that they can raise antibodies against the
parent bacterium. We and others have explored the stabiliza-
tion of the CPS in different ways. MenA CPS analogs in which
the anomeric oxygen of the interglycosidic phosphodiester
bond is replaced with a methylene group to obtain non-
hydrolysable C-phosphono analogs of MenA CPS oligomers
have been reported and mimics, in which the ring-oxygen is
replaced by a methylene group, have also been conceived30,31.
We previously generated short oligomers of these carbaMenA
analogs, containing up to three repeating units (Fig. 1)32. We
showed that IgG antibodies could be raised using a protein
conjugate of the carbaMenA oligomer with a degree of poly-
merization of 3 (i.e., with three repeating units, DP3) that were
capable of recognizing the native MenA CPS33. However, the
carbaMenA DP3 showed poor potential in inhibiting the
binding of anti-MenA CPS antibodies with the capsule, indi-
cating the trimer to be a relatively poor synthetic antigen.
Previous work delivering “natural” synthetic MenA fragments
has shown that short oligos (4 repeating units) can be recog-
nized by anti-MenA antibodies but the minimal epitope capable
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Fig. 1 Structure of MenA CPS and carbaMenA. a Native CPS repeating unit
and b target MenA carba analogs.
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of inducing a strong immune response in immunization
experiments remains to be determined26. To improve the effi-
cacy of the carbaMenA antigens, here we describe the genera-
tion of longer oligomers, assembled using phosphoramidite
chemistry. To this end oligomers up to 8 repeating units in
length are evaluated as potential synthetic antigens (Fig. 1).
CarbaMenA DP8 proves to be a lead antigen, capable of binding
antibodies raised against the natural polysaccharide as well as to
a functional monoclonal antibody. However, its CRM197 con-
jugate elicits in vivo antibodies recognizing the deacetylated
polysaccharide but not the natural MenA capsule. Introduction
of acetyl esters in the carbaMenA DP8 glycomimetic is
demonstrated crucial to improve the MenA polysaccharide
mimicry34,35, as the CRM197 conjugate of the Ac-carbaMenA
DP8 leads to a high level of functional anti-MenA CPS anti-
bodies, equal to the MenA vaccine benchmark. This work thus
presents a proof-of-principle glycomimetic vaccine with activity
that matches the conjugate based on the natural polysaccharide.
Results
Chemical synthesis of the nonacetylated carba analogs. Pre-
viously, we synthesized nonacetylated MenA carba-oligomers up
to three repeating units using H-phosphonate methodology32,36.
We envisaged that for longer fragments (oligomers 1-8, Fig. 2a)
the use of phosphoramidite building blocks would be more
effective for the formation of the phosphodiester linkages37,38. In
line with contemporary DNA chemistry and building on our
recent experience in the generation of synthetic oligo(glycer-
olphosphate) and oligo(ribitolphosphate) teichoic acid antigens,
we opted for the use of the dimethoxytrityl (DMTr) ether to
temporarily mask the primary alcohol functions to be elon-
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CarbaDP6-CRM: R1,R2= H; n = 16.9
CarbaDP8-CRM: R1,R2= H; n = 10.4




Fig. 2 A: oligomer assembly. a TBAF, THF, 0 °C→ rt, 92%. b NaOMe, MeOH, rt, 85%. c DMTrCl, Et3N, DCM, rt, 91%. d 2-cyanoethyl N,N-diisopropyl-
chlorophosphoramidite, N,N-diisopropylethylamine, DCM, rt, 13 (94%). e I. 14, DCI, MeCN, II. CSO, MeCN, III. TCA, DCM, H2O, 94%. f I. 13, DCI, MeCN,
II. CSO, MeCN, III. TCA, DCM, H2O, 16 (82%), 17 (95%), 18 (90%), 19 (92%), 20 (88%), 21 (86%), 22 (87%). g NH4OH, H2O, dioxane. h H2, Pd black,
H2O, AcOH, 1 (99%), 2 (76%), 3 (69%), 4 (39%), 5 (88%), 6 (83%), 7 (77%), 8 (44%). i (Boc)2O, NaHCO3, rt, 16 h. j Ac2O/imidazole, 40 °C, ~9d.
k TFA, rt, 1 h 56% over 3 steps. B: Conjugation to carrier protein. l di-N-hydroxysuccinimidyl adipate, TEA, DMSO. (m) CRM197, NaPi pH= 7.2.
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three-step sequence, comprising the coupling of the phosphor-
amidite with the growing chain alcohol, oxidation of the inter-
mediate phosphite to the corresponding phosphotriester and
unmasking of the primary hydroxyl on the (n+ 1) oligomer. As
illustrated in Scheme 1, the key elongation building block 13 is
obtained from intermediate 12, which in turn is derived in three
steps from known carbasugar 932. The latter carba mannose
building block can be prepared from the commercially avail-
able 3,4,6-tri-O-acetyl-D-glucal as we recently reported32. Thus,
the primary silyl ether and acetyl ester were removed from
compound 9 by the consecutive action of tetrabutylammonium
fluoride and NaOMe, to give diol 11 in 78% yield over two steps.
Next the DMTr group was regioselectively introduced providing
alcohol 12 in 91% yield. This compound was converted into the
elongation block phosphoramidite 13 in 94% yield by reaction
with 2-cyanoethyl-N,N-diisopropyl-chlorophosphoramidite.
With the building block in hand, the target oligomers were
assembled. The synthesis started with the installation of the
aminohexanol spacer on alcohol 12 using known phosphorami-
dite 1438. The building blocks were coupled in a two-step one pot
reaction using dicyanoimidazole (DCI) for activation of the
phosphoramidite. Oxidation of the in situ formed phosphite was
carried out with (1 S)-(+)-(10-camphorsulfonyl)-oxaziridine
(CSO). DCI (pKa 5.2) was preferred over the conventionally
used tetrazole (pKa 4.9), because its lower acidity appeared more
suited to preserve the acid labile DMTr group. CSO was used
instead of iodine because of its higher solubility in nonaqueous
solvents such as acetonitrile. The crude phophotriester was
treated with trichloroacetic acid (TCA) to cleave the DMTr group
and the product was purified by size-exclusion chromatography
(Sephadex LH-20) giving the spacer-equipped monomer 15 in
94% yield. The subsequent couplings were all performed
following the procedure described above. For elongation of the
longer oligomers (n > 1), a larger amount of the phosphoramidite
13 was used and the coupling reaction time was increased to
ensure complete conversion of the alcohol. The yield for each
elongation cycle was good to excellent, ranging between 82 and
95%. Octamer 22 was obtained in 40% overall yield starting from
12. Fragments 16-22 were deprotected using a two-steps
sequence. First the cyanoethyl groups (OCE) were removed
using an aqueous ammonia solution (33%). Next, all remaining
protecting groups (the benzyl ethers and carboxybenzyl carba-
mate) on the so-formed phosphodiesters were cleaved off
by hydrogenolysis over palladium black, to give the target
oligomers 1–8.
Stability study of carbaMenA DP8. The reduction of the poly-
saccharide size over the time could be detrimental for vaccine
activity. To confirm the predicted higher stability of carbaMenA
analogs we undertook an accelerated stability study, monitoring
the change of chain length in buffered 5 mM sodium acetate pH 7
at 37 °C.19 The results of the accelerated stability studies are
generally considered predictive of the behavior at the recom-
mended storage temperature (usually 2–8 °C)22. Compound 8
was compared to the natural polysaccharide portion with an
average DP (avDP) of ~15, obtained according to reported pro-
cedures43, and the corresponding de-O-acetylated form (deOAc),
prepared by treatment of the same fragment with 0.5 M NaOH.
1H and 31P NMR spectra were recorded at day 0, 7, 14, 21, and 28
(+56 for the carba structure), and results are reported in Fig. 3 as
a function of ΔDP (DP starting material-DP at the time point).
The avDP of the two fragments deriving from polysaccharide was
obtained from the 31P NMR signals and expressed as [(PInt/PTer)
+ 1], where PInt is molar concentration of the internal phosphate
groups (phosphodiester groups) and PTer the molar concentration
of terminal phosphate groups (phosphomonoester groups) as
previously reported19. In the 31P NMR spectrum the 31P
monoester signal typically appears at δ 1–5 ppm44. The carba
DP8 exhibited neither change in the 1H NMR-spectrum nor
detectable appearance of monoester peaks at the 31P NMR at day
56 (Supplementary Figs. 1 and 2). Treatment of this sample with
0.5 M NaOH, at 37 °C for 3 days was performed for complete
hydrolysis of the structure into monomers. This generated two
monoesters peaks at 3.80 and 5.10 ppm, respectively, which were
assigned to the phosphorylated H-1 positions of the monomers
and linker deriving from hydrolysis. In contrast, the intensity of
the monoesters signals relative to the phosphorylated H-1 of the
OAc and de-O-acetylated (deOAc) MenA fragments at 3.73 and
4.20 ppm, respectively, clearly increased over the time. A dra-
matic size reduction was found particularly for the nonacetylated
avDP~15 fragment, which dropped down to avDP7 already at day
28. This clearly proved the effect of replacement of the ring
oxygen with a methylene in stabilizing the molecule. A less severe
reduction in size was observed for the acetylated natural MenA
avDP~15 fragment, whose avDP decreased from 18 to 12.8 at day
28, as previously reported, highlighting a possible role of the
electronwithdrawing acetyl substituent in stabilizing the natural
polymer19.
In vitro selection of oligomer length. An important prerequisite
for the immunogenicity of the carba analogs is their ability to
mimic the natural MenA CPS. To investigate this property
in vitro, binding of oligomers with the different length to a
bactericidal anti-MenA mAb (JW-A1)45–47 in comparison to CPS
and a medium length oligomer with avDP ~15 was tested
(Fig. 4a). Remarkably, while DPs from 4 to 7 did not recognize
the mAb, binding was observed with DP8, although with 4 orders
of magnitude higher IC50 compared to the native CPS. De-O-
acetylation of MenA CPS led to diminished recognition, sig-
nifying the specificity of the mAb for acetylated epitopes. A
similar behavior was observed when the inhibitors were assayed
with an anti-MenA polyclonal serum generated by immunization
of mice with a MenA-CRM197 conjugate (Fig. 4b), when the carba
DP8 performed as inhibitor comparably to the deOAc CPS. This
corroborated the propensity of carba DP8 to anti-MenA antibody
binding. The different fragments were then tested against an anti-
deOAc MenA serum (Supplementary Fig. 3). In this case the
deOAc CPS (IC50= 1.86 × 10−6) inhibited similarly to the Ac
counterpart (Supplementary Table 1), indicating the specificity of
the serum for the CPS backbone independently of the acetylation
pattern. Most importantly, recognition was observed for all the
carba DP4-8 analogs, demonstrating that they all resembled
deacetylated MenA CPS portions. Of note, the binding affinity of
carba DP8 (IC50= 1.59 × 10−2 mM) was one order of magnitude
higher than DP7 (IC50= 1.84 × 10−1 mM). Based on these results
DP8 and DP6 were selected for conjugation to carrier protein to
compare the capacity of the two oligomers to elicit antibodies in
mice, the first clearly binding to anti-MenA antibodies and the
latter showing no recognition.
Conjugation of carbaMenA DP6 and DP8 to CRM197. Com-
pounds 6 and 8 were coupled to CRM197 using a conjugation
procedure previously reported, taking advantage of the di-N-
hydroxysuccinimidyl adipate linker (Fig. 2b)48,49. Conjugates
produced by this method are known not to elicit anti-linker
antibodies50. After treatment of the amines of 6 and 8 with the
spacer in DMSO containing triethylamine, the obtained activated
oligomer was purified by co-precipitation with acetone and used
for conjugation. Overnight incubation with CRM197 at a 100:1
glycan/protein molar ratio (corresponding to ̴40-50 active ester:
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protein, as determined by NHS spectrophotometric quantifica-
tion) in buffered pH 7.2 solution, gave the desired neo-glyco-
conjugate, as assessed by SDS page gel electrophoresis
(Supplementary Fig. 4), which was purified by dialysis against a
30 kDaMW cutoff membrane51. A saccharide/protein molar ratio
of 16.9 and 10.4 was determined by MALDI TOF MS for the two
conjugates from carba DP6 and DP8, respectively.
Immunogenicity of the carbaMenA CRM197 conjugates. To test
the immunogenicity of the conjugated carbaMenA DP6 and DP8,
groups of eight BALB/c female mice were immunized with the
neoglycoconjugates. Conjugates prepared as previously described
from sized MenA polysaccharide with avDP8.5 and ~15 were
used as controls33. Mice received three subcutaneously (s.c.) doses
(2 µg on saccharide base), two weeks apart. The neo-
glycoconjugate induced an immune response at week 3, as
observed by assaying the sera elicited by the conjugate against the
same product coated on ELISA plates (Supplementary Fig. 5). At
the serum dilutions tested no anti-CRM197 antibodies were
detectable. Each of the conjugates gave antibodies recognizing the
conjugated hapten and the specificity of this recognition was
confirmed by competitive ELISA (Supplementary Fig. 5). The
binding of the anti-carbaMenA DP8 serum was inhibited by the
unconjugated octamer to a greater extent than its conjugated
form, due to the multivalent exposition of the hapten. Further-
more, this binding was inhibited for ~25% by the deOAc CPS and
almost equally by the naturally acetylated counterpart, antici-
pating the potential of the raised antibodies in recognizing the
capsule structure. To determine the capacity of the elicited anti-
bodies to cross-react with the backbone CPS structure deprived of
the acetyl substituents, the sera were assayed against the non-
acetylated CPS conjugated to Human Serum Albumin (HSA).
The carbaMenA conjugates clearly showed an anti-deOAc CPS
immune response, but IgG titers were inferior to those elicited by
the conjugated avDP8.5 and ~15 used as controls (p ≤ 0.003,
Fig. 5b). The response of the two carba analogs conjugates was
not statistical different, however the number of responder mice to
the DP8 conjugate was higher than for the DP6 conjugate.
When the ELISA was conducted using the acetylated CPS as
coating reagent, the difference between the anti-native MenA IgG
titers elicited by the carbaMenA DP6 and DP8 neoglycoconju-
gates and the controls was even more evident (p < 0.0001, Fig. 5a).
The functionality of the elicited antibodies was next assessed on
pooled sera by measuring the complement mediate lysis of
bacteria expressing the acetylated CPS, as reported in
literature33,52. This assay is considered predictive of protection














Fig. 3 Stability of carba DP8. The sugar analog was compared to acetylated and de-O-acetylated MenA CPS avDP–15 at 37 °C in 5 mM NaOAc pH 7; ΔDP
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Fig. 4 Inhibition of the binding of anti-MenA antibodies to CPS. Competitive ELISA with anti-MenA mAb (a) and anti-MenA polyclonal serum (b) using
different length nonacetylated carbaMenA oligomers as inhibitors and CPS as coating. c Competitive SPR of binding between anti-MenA mAb and
immobilized biotylinated CPS. Inhibitors were reported as described: red curve for MenA CPS; blue curve MenA avDP–15; light blue curve MenA DP8;
brown curve MenA deOAc CPS; green curve carba DP8; dark green curve carbaDP8 OAc; purple curve carba DP4; light purple carba DP6; orange curve
carba DP7; yellow curve negative control. MenA CPS and deOAc CPS were the positive controls and the β-glucan Laminarin was the negative control in a
and b. MenA CPS and fragments thereof were used as positive controls and anti-MenC mAb was flown on the chip as negative control in c. Data from a
single experiment representative of two experiments is shown.
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bactericidal activity for the pooled serum from responder mice
raised using the carbaMenA DP6 and DP8 conjugates (1024 vs
512, respectively). When the Serum Bactericidal Activity (SBA)
was measured using human complement, the carba DP8-CRM197
showed a titer of 128, significantly lower that the SBA of serum
generated by the benchmark vaccine, based on the natural MenA
CPS avDP~15. These results are in line with the observation
reported in literature that antibodies elicited by a conjugate of the
deOAc MenA CPS are scarcely functional35.
Taken together, this data revealed that the carbaMenA DP8 is
an effective, stable mimic of the MenA CPS, capable of binding
anti-MenA CPS antibodies. The carbaMenA DP8 conjugate
induced antibodies able to activate human complement deposi-
tion, while the carbaMenA DP6 did not, highlighting the DP8
molecule as lead antigen. The carbaMenA DP8 neoglycoconju-
gate vaccine, however, elicited only low levels of bactericidal anti-
MenA antibodies. Considering that the MenA CPS is variably O-
acetylated at position 3 and 4, we therefore sought to further
increase the resemblance to the natural polysaccharide and
increase the generation of protective antibodies by randomly O-
acetylating the carbaMenA DP8 lead molecule.
Optimization of the glycomimetic vaccine candidate. To
introduce acetyl esters on carbaMenA DP8, we first installed a
temporary Boc protecting group on the amine group of the linker
(Fig. 2a). The resulting compound was next carefully acetylated
by treatment with Ac2O/imidazole to reach an acetylation level of
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Fig. 5 Immune response elicited by the neo-glycoconjugates. Antibody titers are reported in the a–c panel as Geometric Mean (horizontal bar) with the
95% of CI (vertical bar). rSBA titers are reported in the d panel as Geometric Mean (horizontal bar) with the 95% of CI (vertical bar). Two-tailed Mann-
Whitney test was used to compare ranks; n= 10. Pre-immune was the negative control in both type of analysis. a Anti-MenA IgG titers estimated in
individual murine sera after the second boost against the natural MenA CPS. p < 0.0001 between avDP~15 MenA and carbaDP6/DP8 conjugates. b Anti-
deOAc MenA IgG titers determined against the de-O-acetylated MenA CPS conjugated to HSA. p= 0.002 between avDP~15 and carbaDP8 conjugates,
and between avDP8.5 and carbaDP6 conjugates; p= 0.003 between avDP8.5 and carbaDP8 conjugates; and p= 0.004 between avDP~15 and carbaDP6
conjugates comparison. c Anti-MenA IgG titers estimated in individual sera after the second boost using MenA CPS for coating. p= 0.0011 comparing
avDP15 and Ac-carbaDP8 conjugates. d Human and rabbit serum bactericidal titers measured after the third injection on pooled and individual mice sera,
respectively. Not significant differences were found comparing the ranks. Immunizations were conducted in duplicates and data from a representative
experiment are here shown. *Human and rabbit SBA titers measured after the third injection on pooled sera; **Human and rabbit SBA titers measured after
the third injection on pooled sera from responder mice.
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provided the conjugation-ready Ac-carbaMenA DP8 8c. NMR
analysis revealed the acetyls to reside on either the C-3 or C-4
positions, with also concomitant acetylation at C-3/4 up to an
extent of 44% (see Supplementary Fig. 6 and other Supplemental
Information for full characterization). To test this compound as a
potential antigen, we first evaluated binding with the anti-MenA
CPS mAb, in a competitive Surface Plasmon Resonance (SPR)
experiment (Fig. 4c). This SPR was optimized to increase the
sensitivity of the assay compared to the previously done standard
ELISA. As shown in Fig. 5c, Ac-carbaMenA DP8 8c exhibited a 4-
log higher capacity as inhibitor compared to its nonacetylated
counterpart 8, and binding to the mAb was almost comparable to
the natural avDP8 and avDP~15 oligomers. Based on this pro-
mising result, 8c was conjugated to CRM197 through the two-step
procedure used for the nonacetylated oligomers, involving reac-
tion with the di-N-hydroxysuccinimidyl adipate spacer and
incubation with CRM197, in 13:1 active ester: protein molar ratio,
based on NHS spectrophotometric quantification (Fig. 2b). The
purified neo-glycoconjugate was used in an immunization study
with ten BALB/c female mice, using the avDP~15 CRM197 con-
jugate as comparator. After three s.c. injections (2 µg on sac-
charide base), the sera were collected and analyzed for the content
of bactericidal IgGs (Fig. 5c).
Remarkably, the Ac-carbaMenA DP8 conjugate induced higher
levels of anti-MenA CPS antibodies compared to the control. SBA
titers analyzed in individual mice also showed that the synthetic
antigen was able to induce rabbit complement mediated
bactericidal killing of MenA bacteria statistically noninferior to
the vaccine benchmark (Fig. 5d). Analysis in pooled sera
confirmed that the human complement mediated bactericidal
activity was also comparable between Ac-carbaMenA DP8 and
the natural avDP~15, revealing Ac-carbaMenA DP8 as a true and
potent mimic of the MenA CPS, that can be used in the
generation of a stabilized neoglycoconjugate vaccine.
Discussion
The availability of stable MenA polysaccharide analogs is very
attractive for the development of a stable MenA glycoconjugate
vaccine. To overcome the intrinsic lability of the anomeric
phosphodiester linkages that connect the repeating units in the
natural CPS, we have replaced the ring-oxygen of the constituting
N-Acetyl mannosamines for a methylene entity, thereby gen-
erating carbaMenA oligomers. Using tailor made phosphor-
amidite building blocks we have prepared oligomers ranging from
1 to 8 monomers in length, each equipped with a chemoselective
ligation handle. The substitution of the ring oxygen with a
methylene in the carba-analogs resulted in a much higher stabi-
lity, particularly when compared to the nonacetylated natural
CPS fragment. CarbaMenA oligomers in the rage of DP4-8
inhibited the recognition of anti-de-OAc MenA antibodies
directed to the deacetylated backbone of the capsule in a length-
dependent manner. However, only carbaMenA DP8 competed
for binding of an anti-MenA functional mAb, indicating that 8
repeating units are required to provide an effective synthetic
antigen. While in silico analysis of carbaMenA related monomers
has shown similar conformations with the natural sugar54, studies
with oligomers up to the dodecamer have indicated that these
longer structures may adopt a different overall conformation than
their natural counterparts55. The results presented here show that
the carbaMenA can adequately mimic the natural polysaccharide.
A CRM197 conjugate of the nonacetylated carba-MenA DP6
and DP8 were generated and used to induce murine antibodies
that not only recognized the haptens which they were induced to,
but were also capable of cross-reacting with the nonacetylated
CPS backbone. However, only moderate levels of antiacetylated
CPS IgGs, able to induce in vitro rabbit complement mediated
bactericidal activity, were raised. Remarkably, serum from the
carbaMenA DP8 conjugate was able to active human complement
deposition. To further improve on its activity, the carbaMenA
DP8 candidate was optimized by randomly acetylating the
structure at a level comparable to the natural CPS. The structure
exhibited a 4-log higher capacity to inhibit the binding of a
protective mAb with the MenA CPS compared to its non-
acetylated form. Most importantly, after conjugation to CRM197
the randomly acetylated carbaMenA DP8 elicited high level of
anti-MenA CPS antibodies with bactericidal activity comparable
to the MenA vaccine benchmark.
Synthetic oligosaccharides are widely explored as surrogates for
natural polysaccharides in the generation of anti-bacterial vac-
cines. Generally, all these synthetic structures try to accurately
duplicate their natural counterparts. We now show that synthetic
chemistry can deliver mimetics with improved, tailor-made fea-
tures, opening up new avenues in the design of carbohydrate-
based vaccines23. Considering that the random O-acetylation at
C3 and C4 proved essential to fully resemble the natural MenA
polysaccharide, the role of these positions in the immunogenicity
will deserve further studies18. Future efforts will be directed at the
site-selective acetylation of the lead antigen carbaMenA DP8. The
chemistry developed here will allow for the assembly of (acetyl
functionalized) carbaMenA oligomers through automated
syntheses protocols to generate a larger library of potential syn-
thetic antigens to define the precise pattern responsible for the
herein reported strong immune response.
Methods
General procedure A. Phosphoramidite coupling, oxidation, and detritylation on
a typical scale (0.03–0.3 mmol): Starting alcohol was coevaporated 3 times with
ACN, and was added freshly activated MS3Å and DCI (0.25 M solution in ACN,
1.5 eq). The solution was stirred for 15 min. To the mixture was added phos-
phoramidite reagent (0.1–0.16M solution in ACN, 1.3–3 eq) and stirred until the
total conversion of the starting material (≈2 h). Subsequently CSO (0.5 M solution
in ACN, 2eq) was added to the reaction mixture and stirred for 15 min. The
mixture was diluted with EtOAc and washed with a 1:1 solution of brine/NaHCO3.
The water layer was extracted 2 times with EtOAc. The organic layer was dried
over Na2SO4 and concentrated in vacuo. The crude was coevaporated 3 times with
ACN and dissolved in DCM (5–10 mL). To the solution was added TCA (0.18 M
solution in DCM) and stirred for 1 h. To the reaction mixture was added H2O and
stirred for 15 min. The reaction was washed with a 1:1 solution of brine/NaHCO3.
The water layer was extracted with DCM 3 times. The organic layer was dried over
Na2SO4 and concentrated in vacuo. The crude was purified by flash chromato-
graphy (DCM/Acetone) or by size exclusion chromatography (Sephadex LH-20,
MeOH/DCM 1:1).
General procedure B. Deprotection on a typical scale (5–40 µmol): Starting
alcohol was dissolved in NH3 (aqueous solution 30–33%, 1 mL per 10 µmol) and
dioxane (until it completely dissolved). The reaction mixture was stirred for 2 h.
The mixture was concentrated in vacuo. 1H NMR and 31P NMR analysis showed a
total conversion to the semi-protected intermediate. The crude was dissolved in
MilliQ H2O and eluted through a column containing Dowex Na+ cation-exchange
resin (type: 50WX4-200, stored on a 0.5 M NaOH in H2O, flushed with MilliQ
H2O and MeOH before use). The crude was dissolved in MilliQ H2O (2 mL per
10 µmol). To the reaction mixture was added 4–5 drops of glacial AcOH. The
mixture was purged with Ar. To the solution was added a scup of Pd black. The
reaction mixture was purged with H2 for a few seconds and stirred under H2
atmosphere for 3 days. To the mixture was added celite. The solution was filtrated
and concentrated in vacuo. The crude was purified by size-exclusion chromato-
graphy (Toyopearl HW-40). The pure compound was dissolved in MilliQ H2O,
eluted through a column containing Dowex Na+ cation-exchange resin (type:
50WX4-200, stored on a 0.5 M NaOH in H2O, flushed with MilliQ H2O and
MeOH before use) and lyophilized.
Preparation of neoglycoconjugates. In a typical experiment, 5–10 mg of the
amino-oligosaccharides were vacuum dried, solubilized in 1:9 H2O: DMSO solu-
tion to a final amino group concentration of 40 mmol mL−1, and reacted with a 12-
fold molar excess of di-N-hydroxysuccinimidyl adipate linker (SIDEA), in presence
of fivefold molar excess triethylamine as compared with amino groups. The
reaction was kept under gentle stirring at room temperature for 3 h. The activated
oligosaccharides were purified by precipitation with four volumes of ethyl acetate
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followed by ten washes of the pellet with 1 mL of the same solvent. Finally the pellet
was dried under vacuum, and the content of introduced N-hydroxysuccinimide
ester groups was determined44.
Conjugates were prepared in 50 mM NaH2PO4 pH 7 using an active ester:
protein molar ratio of 40-50:1 for 6 and 8 and 13:1 for 8c, at the final protein
concentration of 40 mgmL−1. The reaction was kept overnight at room
temperature with gentle stirring. The conjugates were purified by tangential flow
filtration (Vivaspin) using a cutoff of 30 kDa and using PBS pH 7.2 as buffer.
Conjugates were characterized by micro BCA for total protein content and by
MALDI analysis for total saccharide content.
Mice immunization and ELISA analysis. Experiments were undertaken in
accordance with the regulations of the Directive 2010/63/EU and GSK ethical
guidelines, under approval of the Italian Ministry of Health. All mice were housed
under specific pathogen-free conditions at the GSK Vaccines Animal Resource
Centre. Antigens formulations have been prepared under sterile conditions. Groups
of 10 BALB/c mice were immunized on days 1, 14 and 28; bleedings were per-
formed on day 0 (pre immune), day 27 (post 2) and day 42 (post 3). Vaccines were
administered in saccharide dose and the dosage of 2 μg/mice per dose in terms of
saccharide. Adjuvant AlPO4 was used at the dose of 0.12 mg of Al3+. The antibody
response induced by the glycoconjugates has been measured by ELISA. The pre-
immune serum was used as negative control in this analysis. Plates were coated
with HSA-deOAc or MenA CPS by adding 100 μL/well of a 5 μg mL−1 poly-
saccharide solution in PBS buffer at pH 8.2 followed by incubation overnight at
4 °C46. HSA-deOAc MenA CPS, CRM197 conjugates and CRM197 were coated at
the protein concentration of 2 μg mL−1 in pH 7.2 PBS buffer. Coating solutions
were removed from the plates by washing tree times with PBS buffer with 0.05% of
Tween 20 (Sigma) (TPBS). A blocking step was then performed by adding 100 μL/
well of BSA solution at 3% in TPBS and incubating the plates 1 h at 37 °C. Blocking
solution was removed from the plates by washing three times with TPBS. A 200 μL/
well of pre-diluted serum (1:25 for pre immune negative control, 1:200/1:500 for a
reference serum and from 1:25/1:200 for test sera) was added in the first well of
each column of the plate, while on the other wells 100 μL of TPBS was dispensed.
Eight two-fold serial dilutions along each column were then performed by trans-
ferring from well to well 100 μL of sera solutions. After primary antibody dilution,
plates were incubated for 2 h at 37 °C. Three washes with TPBS, 100 μL/well TPBS
solutions of secondary antibody alkaline phosphates conjugates (anti mouse IgG
1:10000, Sigma-Aldrich) were then added, and the plates incubated 1 h at 37 °C.
After three more washes with TPBS, 100 μL/well of a 1 mgmL−1 of p-NPP (Sigma)
in a 0.5 M di-ethanolamine buffer pH 9.6 was added. Finally, plates were incubated
for 30 min at room temperature and read at 405 nm using the plate reader Spec-
tramax 190. Sera titers were expressed as the reciprocal of sera dilution corre-
sponding to a cut-off OD= 1.
Each immunization group has been represented as the geometrical mean
(GMT) with 95% CI of the single mouse titers. The statistical and graphical analysis
has been done by GraphPad Prism 7 software.
In vitro bactericidal assay. Functional antibodies induced by vaccine immuni-
zation were analyzed by measuring the complement-mediated lysis of N. menin-
gitidis with an in vitro bactericidal assay56. A commercial lot of baby rabbit
complement (Peel Freeze Biological, cod. 31061) was used as source of active
complement for rSBA. The use of human complement samples deriving from the
study protocol V72_92 was authorized by GSK HBS Reuse Check Team and
performed upon written informed consent obtained from participants before the
study-specific procedures.
N. meningitidis strain was grown overnight on chocolate agar plates at 37 °C in
5% CO2. Colonies were inoculated in Mueller-Hinton broth, containing 0.25%
glucose to reach an OD600 of 0.05-0.08 and incubated at 37 °C with shaking. When
bacterial suspensions reached OD600 of 0.25–0.27, bacteria were diluted in the
assay buffer (DPBS with 1 % BSA and 0.1% glucose) at the working dilution
(ca. 104 CFU mL−1). The total volume in each well was 50 μL with 25 μL of serial
two-fold dilutions of the test serum, 12.5 μL of bacteria at the working dilution and
12.5 μL of complement source. The tested sera were pooled and heat-inactivated for
30 minutes at 56 °C. Negative controls included bacteria incubated, separately, with
the complement serum without the test serum and with test sera and the heat-
inactivated complement. Immediately after the addition of the baby rabbit
complement, negative controls were plated on Mueller-Hinton agar plates, using
the tilt method (time 0). The microtiter plate was incubated for 1 h at 37 °C, then
each sample was spotted in duplicate on Mueller-Hinton agar plates while the
controls were plated using the tilt method (time 1). Agar plates were incubated
overnight at 37 °C and the colonies corresponding to time 0 and time 1 (surviving
bacteria) were counted. The serum bactericidal titers was defined as the serum
dilution resulting in 50% decrease in colony forming units (CFU) per mL, after
60 min incubation of bacteria in the reaction mixture, compared to control CFU
per mL at time 0. Typically, bacteria incubated without the test either pooled or
individual murine serum in the presence of complement (negative control) showed
a 150–200% increase in CFU mL−1, during the 60 min incubation time. The
reference strain for meningococcal serotype A was F823857.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the paper and its Supplementary Information files. Source data are provided with
this paper.
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